Protagonist Therapeutics, Inc
No enriched coverage for $PTGX in the last 7 days.
PATEL DINESH V PH D (President and CEO) sold 100,000 shares of Protagonist Therapeutics, Inc (PTGX) at an average of $148.91 ($148.52–$149.11, $14.89M total) across 2 trades over 2026-08-10 to 2026-08-11 under a Rule 10b5-1 trading plan.
Analyst actions on Monday included Bank of America reiterating Nvidia as Buy ahead of earnings, with ~16x CY27 forward P/E. Loop raised FirstCash Holdings to Buy, PT $255, and cut Domino’s to Hold, PT $353. UBS reiterated Micron Buy, PT $1,625. Jefferies downgraded Apple to underperform. Citi reiterated SpaceX Buy, PT $200. Bernstein raised Microsoft PT to $660.
Analysts at Barclays and others updated views on healthcare stocks. Protagonist Therapeutics (PTGX): Barclays reiterated Buy, $153 target; TipRanks consensus Strong Buy, $133 average; TipRanks upgraded to Buy with $151 target. Qiagen (QGEN): Barclays Hold, $38 target; consensus Moderate Buy, $42.48. Envista Holdings (NVST): Barclays Buy, $32 target; consensus Moderate Buy, $30; BofA Buy, $34.
Recent PTGX coverage spans insider activity, financial news and earnings.
In the last 30 days, PTGX insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($14.9M). The most active reporter was PATEL DINESH V PH D, President and CEO, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The filing discloses a large CEO open-market sale under a 10b5-1 plan, which can modestly affect near-term sentiment but is not itself a fundamental change.
Upgrade after earnings suggests the post-earnings read-through improved, supporting a re-rating thesis.
Street targets cluster in the low-$150s, supporting near-term sentiment but offering no new fundamental catalyst beyond analyst target changes.
Near-term catalyst is the FDA decision window for rusfertide in August 2026, alongside ongoing commercial ramp for ICOTYDE and pipeline advancement timing into 2027.
PTGX’s catalyst stack is framed around 2H26 Phase 3 data plus an August 2026 approval-related event.
alphai scores every news story that mentions PTGX with an AI model for sentiment and relevance, and aggregates insider trades from Protagonist Therapeutics, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
PATEL DINESH V PH D (President and CEO) sold 100,000 shares of Protagonist Therapeutics, Inc (PTGX) at an average of $148.91 ($148.52–$149.11, $14.89M total) across 2 trades over 2026-08-10 to 2026-08-11 under a Rule 10b5-1 trading plan.
2 min readAnalyst actions on Monday included Bank of America reiterating Nvidia as Buy ahead of earnings, with ~16x CY27 forward P/E. Loop raised FirstCash Holdings to Buy, PT $255, and cut Domino’s to Hold, PT $353. UBS reiterated Micron Buy, PT $1,625. Jefferies downgraded Apple to underperform. Citi reiterated SpaceX Buy, PT $200. Bernstein raised Microsoft PT to $660.
2 min readAnalysts at Barclays and others updated views on healthcare stocks. Protagonist Therapeutics (PTGX): Barclays reiterated Buy, $153 target; TipRanks consensus Strong Buy, $133 average; TipRanks upgraded to Buy with $151 target. Qiagen (QGEN): Barclays Hold, $38 target; consensus Moderate Buy, $42.48. Envista Holdings (NVST): Barclays Buy, $32 target; consensus Moderate Buy, $30; BofA Buy, $34.
3 min readProtagonist Therapeutics, Inc (PTGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early Adoption Rusfertide NDA under Priority Review for Polycythemia Vera; PDUFA Date in August 2026 Comprehensive Phas
6 min readClear Street names five biotech stocks for 2H 2026 catalysts: MoonLake (MLTX) Buy, $70 target; Cullinan (CGEM) Buy, $46; Zura Bio (ZURA) Buy, $18; Arrivent (AVBP) Buy, $47; Protagonist (PTGX) Buy, $116. It cites planned clinical readouts and regulatory milestones, plus MLTX’s ~$200M offering and AVBP’s up to $250M ATM filing.
7 min readWaddill William D. sold 9,000 shares of Protagonist Therapeutics, Inc (PTGX) at $117.94 ($1.06M total) on 2026-06-23 under a Rule 10b5-1 trading plan.
2 min readProtagonist Therapeutics, Inc (PTGX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2618251d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Protagonist Therapeutics, Inc. 2026 Equity Incentive Plan Adopted By The Board Of Directors: March 24, 2026 Approved by the Stockholders: June 17, 2026 1. General. (a) Successor to and Continuation of Prior Plan. The Plan
2 min readWaddill William D. sold 9,000 shares of Protagonist Therapeutics, Inc (PTGX) at $107.68 ($0.97M total) on 2026-06-10 under a Rule 10b5-1 trading plan.
1 min readWaddill William D. sold 9,000 shares of Protagonist Therapeutics, Inc (PTGX) at $99.64 ($0.90M total) on 2026-05-29 under a Rule 10b5-1 trading plan.
2 min readWolfe Research has initiated coverage on Protagonist Therapeutics (NASDAQ: PTGX) with an outperform rating and a price target of $135, citing the company's strong early-stage pipeline and validated biology. The firm anticipates significant catalysts including clinical proof of concept for three wholly-owned assets by early 2027 and highlights potential milestone payments from partners Johnson & Johnson and Takeda. Other analysts from BMO Capital, Citizens, Jefferies, Truist Securities, and Clear Street have also expressed confidence in Protagonist Therapeutics, setting price targets between $116 and $137.
3 min read
